Research Paper Volume 14, Issue 6 pp 2880—2901

A systematic pan-cancer study demonstrates the oncogenic function of heterogeneous nuclear ribonucleoprotein C

class="figure-viewer-img"

Figure 5. Phosphorylation of the HNRNPC protein in a variety of cancers. The UALCAN was used to compare the expression levels of HNRNPC phosphoprotein in normal and primary tissue using the CPTAC dataset. (A) Phosphorylation sites of HNRNPC proteins in breast cancer, including S233, S238, S239, S239S240, S227, S277S228, S228, S240S247, S247 and S293. (B) Phosphorylation sites of HNRNPC proteins in ovarian cancer, including S162, S233, S149 and S220. (C) Phosphorylation sites of HNRNPC proteins in UCEC, including S220, S225 and S247. (D) Phosphorylation sites of HNRNPC proteins in brain cancer, including S220. (E) Phosphorylation sites of HNRNPC proteins in colon cancer, including S162, S233, S238, S239, S240 and S241. (F) Phosphorylation sites of HNRNPC proteins in Lung adenocarcinoma, including S209, S233, S253S260, S196, S230 and S240S247. (G) Phosphorylation sites of HNRNPC proteins in clear cell cancer, including S233, S253S260, S260, S31, S220, S240S247, S247 and S255. Blue box plot: normal tissue; red box plot: tumor tissue; orange box plot: Caucasian; brown box plot: African-American; green box plot: Asian.